IL4 and Alzheimer disease: Calcineurin inhibitors, such as tacrolimus and pimecrolimus, offer symptomatic relief by inhibiting the transcription of critical cytokines (IL-2, IL-4, and IL-5) involved in AD pathogenesis, albeit with lingering concerns regarding their oncogenic potential [18, 24–26].